Immunic, Inc.: diluted weighted-average shares
Diluted weighted-average shares for Immunic, Inc. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All Immunic, Inc. financial histories
What this measure means
Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.
Exact concept: us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2020-01-01 to 2025-12-31. The SEC response was captured on 2026-09-19.
Reading these values
This selected numerical history matches Basic weighted-average shares for the same reporting intervals and original units. The accounting definitions remain distinct. Equal values do not establish that the concepts are interchangeable or explain why they match; filing dates and accessions may differ. Compare the definitions and source filings before combining them.
Context from the filing
Immunic reports equal basic and diluted denominators for 2024 and 2025 because of its net losses. Its EPS note says the denominator includes pre-funded warrants from the January 2024 financing and, for 2025, the May 2025 offering; these are not extra dilution to add again. The note separately lists warrants still unexercised at each year-end, which are not a new weighted-average denominator calculation. Dollar losses are displayed in thousands, while reported share counts and per-share amounts are unscaled. Read the source filing.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| 2025-01-01 | 2025-12-31 | 155,688,030 | shares | 2026-02-26 | 10-K · 0001280776-26-000005 |
| 2024-01-01 | 2024-12-31 | 100,174,766 | shares | 2026-02-26 | 10-K · 0001280776-26-000005 |
| 2023-01-01 | 2023-12-31 | 44,320,050 | shares | 2025-03-31 | 10-K · 0001280776-25-000005 |
| 2022-01-01 | 2022-12-31 | 31,819,006 | shares | 2024-02-22 | 10-K · 0001280776-24-000004 |
| 2021-01-01 | 2021-12-31 | 23,652,779 | shares | 2023-02-23 | 10-K · 0001280776-23-000004 |
| 2020-01-01 | 2020-12-31 | 15,663,826 | shares | 2022-02-24 | 10-K · 0001280776-22-000006 |
Related financial histories
- Immunic, Inc.: total assets
- Immunic, Inc.: total liabilities
- Immunic, Inc.: stockholders equity
- Immunic, Inc.: cash and cash equivalents
- Immunic, Inc.: net income or loss
- Immunic, Inc.: operating cash flow
- Immunic, Inc.: capital expenditure payments
- Immunic, Inc.: financing cash flow
- Immunic, Inc.: investing cash flow
- Immunic, Inc.: retained earnings or deficit
- Immunic, Inc.: basic weighted-average shares
- Immunic, Inc.: basic earnings per share
- Immunic, Inc.: diluted earnings per share
- Immunic, Inc.: net property, plant and equipment
- Immunic, Inc.: share-based compensation expense
- Immunic, Inc.: operating income or loss
- Immunic, Inc.: current assets
- Immunic, Inc.: current liabilities
- Immunic, Inc.: current accounts payable
- Immunic, Inc.: goodwill carrying amount
- Immunic, Inc.: operating expenses
- Immunic, Inc.: research and development expense
Inspect the source
- Entity
- Immunic, Inc. / CIK 0001280776
- Captured
- 2026-09-19T11:17:16.668Z
- SEC response SHA-256
42bd0540222755e6a5b59fb720001467c6d0b0c5e4a134ccad344a613c1b8818
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001280776.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))